Relationship between alirocumab, PCSK9, and LDL-C levels in four Phase 3 ODYSSEY trials using 75 and 150 mg doses

Alirocumab is a monoclonal antibody to PCSK9.

Source: Journal of Clinical Lipidology - October 13, 2019 Category: Lipidology Authors: Jennifer G. Robinson, Michel Farnier, John JP. Kastelein, Eli M. Roth, Marja-Riitta Taskinen, Helen M. Colhoun, Aurelie Brunet, A Thomas DiCioccio, Guillaume Lecorps, Robert Pordy, Marie T. Baccara-Dinet, Christopher P. Cannon Tags: Original Research Source Type: research